Vancomycin dosing in treatment of meningitis

Not Applicable

• Conditions: postneurosurgical meningitis.; Pneumococcal meningitis, Streptococcal meningitis; G00.1, G00

• Registration Number: IRCT2016071114693N6
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

( patients who diagnosed postneurosurgical meningitis and received vancomycin; Age>18 years old)
(Exclusion criteria: chronic kidney disease (creatinine clearance<50 mL/min) before initiate threatment; occurring of acute kidney disease (according to the AKIN); administration of intrathecal vancomycin; through level<15mcg/mL; through level>30mcg/mL)

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CSF vancomycin concentration. Timepoint: day 3 and day 5 of treatment. Method of measurement: mcg/mL, Fluorescent PolarizationImmunoassay, by Cobas system.;Serum concentration of vancomycin. Timepoint: day 3 and 5 of treatment. Method of measurement: mcg/mL, Fluorescent PolarizationImmunoassay, by Cobas system.